Topics:

Novo shares hit after FDA review highlights Tresiba heart risks

Tools

Shares of Novo Nordisk ($NVO) took a hit this morning after the FDA released a review of its long-acting insulin Tresiba (degludec) highlighting a warning that the drug presents a greater risk to the heart than other diabetes medications. That raises the prospect that an outside panel of experts could demand more safety studies when it meets to review Novo's application on Thursday. Novo needs tresiba, a potential blockbuster, to counter growing competition from Sanofi's ($SNY) Lantus, which earned close to $5 billion last year. Just weeks ago an EU panel gave Tresiba a thumbs-up. Story